TL;DR
This study uses a CRISPR activation screen to identify host factors that help SARS-CoV-2 enter cells, revealing that the potassium channel KCNA6 plays a significant role, especially in neuronal cells. This finding not only sheds light on how the virus affects the nervous system but also points to KCNA6 as a potential drug target, with existing FDA-approved drugs showing promise in suppressing viral entry.
What Problem Does This Paper Address?
While vaccines have been successful against SARS-CoV-2, effective treatments for active infections are still needed. A major puzzle is how the virus enters neurons and sensory organs, leading to the diverse neurological symptoms observed in COVID-19 patients. Previous studies using loss-of-function screens have limitations, as they can only identify factors already expressed in the tested cell lines. This paper aims to overcome these limitations by using a gain-of-function approach to discover novel host factors that promote viral entry, particularly in cells where the primary receptor, ACE2, might be absent or at low levels.
Methods
The researchers employed a CRISPR activation (CRISPRa) screening approach. Unlike loss-of-function screens that disable genes, CRISPRa enhances gene expression. They used a system to activate each of the ~6000 human membrane proteins individually in two types of cells: those with and without the ACE2 receptor. These cells were then exposed to SARS-CoV-2 Spike protein-pseudotyped lentiviruses. By observing which gene activations led to increased viral entry, they identified potential host factors. They also used a VSVG-pseudotyped virus as a control to distinguish SARS-CoV-2-specific factors from general lentiviral entry mechanisms. Key validation steps included using replication-competent SARS-CoV-2, analyzing single-cell RNA sequencing data from human nasal tissues, and testing an FDA-approved drug targeting the identified host factor.
Datasets
- Human Olfactory Epithelium scRNA-seq data: Used to examine the expression of identified host factors in relevant human tissues.
- GTEx dataset: Utilized for broad tissue expression analysis of top-ranking genes.
- ~8 million patient insurance claims data (Medicare Advantage Part D): A large-scale retrospective dataset used to investigate the clinical association between drug classes targeting identified host factors and COVID-19 hospitalization risk.
Key Insights and Ideas
- KCNA6 as a key ACE2-independent entry factor: The most striking finding is the identification of KCNA6, a potassium channel, as a potent facilitator of SARS-CoV-2 entry, even in cells lacking ACE2. This suggests a crucial mechanism for viral entry into neuronal and sensory cells, which often have low ACE2 expression.
- Neuronal tropism explained: The high expression of KCNA6 in specific neuronal cell types within the olfactory epithelium, which are known to be infected in COVID-19, provides a compelling explanation for the sensory and neurological symptoms of the disease.
- Druggable target identified: The FDA-approved drug dalfampridine (4-Aminopyridine), a broad-spectrum potassium channel inhibitor, was shown to suppress SARS-CoV-2 entry in a dose-dependent manner, highlighting KCNA6 and related channels as promising therapeutic targets.
- Real-world evidence for drug repurposing: The analysis of millions of patient claims revealed a significant association between the use of certain drug classes, particularly those targeting potassium channels, and a reduced risk of COVID-19 hospitalization, lending strong clinical support to the findings.
Key Results
- CRISPRa screening identified novel host factors, including KCNA6, LGMN (a protease), and HLA-DPB1 (an immune component), that promote SARS-CoV-2 entry.
- Overexpression of KCNA6 increased SARS-CoV-2 infection by up to ~50-fold in ACE2-null cells.
- KCNA6 is highly expressed in OLIG2+/TUJ1+ neurons in the olfactory epithelium, which are sites of COVID-19 infection and have minimal ACE2.
- Dalfampridine inhibited SARS-CoV-2 pseudovirus entry with an IC50 of ~490 µM in ACE2-null cells, and its effect was KCNA6-dependent.
- A retrospective analysis of ~8 million patient claims showed statistically significant associations between drug classes targeting potassium channels and reduced COVID-19 hospitalization risk.
Limitations and Future Work
- Genome annotation issues: The study notes that KCNA6 expression was difficult to detect in some standard datasets (like GTEx) due to overlapping gene annotations, requiring re-processing of data with specific pipelines. This highlights the challenges of accurate gene expression analysis.
- CRISPRa limitations: While powerful, CRISPRa screens might not capture factors that act indirectly or are not membrane-associated. The study used a membrane-focused library, which could miss other types of host factors.
- Future Directions: The authors suggest further investigation into the precise mechanism by which KCNA6 facilitates viral entry, particularly exploring the role of potassium ions in potential conformational changes of the Spike protein, similar to mechanisms observed in other viruses. They also propose that this CRISPRa screening platform can be applied to study other emerging pathogens.
Summary updated